Summary
Synopsys Inc. (SNPS) reported solid financial results for the third quarter and the first nine months of fiscal year 2017, demonstrating continued growth and operational strength. Total revenue increased by 13% year-over-year for both periods, reaching $695.4 million in Q3 and $2.03 billion year-to-date, driven by strong performance across its EDA and IP offerings, as well as contributions from recent acquisitions. The company maintained healthy profitability, with operating income increasing significantly by 37% in Q3. Cash flow from operations remained robust, supporting a strong liquidity position with $1.3 billion in cash, cash equivalents, and short-term investments as of July 31, 2017. The company also continued its commitment to shareholder returns through its active stock repurchase program. While the company navigates a dynamic industry landscape, including potential impacts from customer consolidation and ongoing legal matters, its diversified revenue streams, strong market position, and consistent execution provide a positive outlook. Investors should note the continued shift towards time-based revenue models, which impacts the timing of revenue recognition but ensures a stable recurring revenue base.
Financial Highlights
55 data points| Revenue | $695.38M |
| Cost of Revenue | $169.55M |
| Gross Profit | $525.84M |
| R&D Expenses | $228.66M |
| Operating Expenses | $420.46M |
| Operating Income | $105.37M |
| Interest Expense | $2.32M |
| Net Income | $116.75M |
| EPS (Basic) | $0.78 |
| EPS (Diluted) | $0.75 |
| Shares Outstanding (Basic) | 150.21M |
| Shares Outstanding (Diluted) | 154.68M |
Key Highlights
- 1Total revenue grew 13% year-over-year to $695.4 million for Q3 FY2017 and $2.03 billion for the first nine months.
- 2Operating income saw a substantial increase of 37% in Q3 FY2017 compared to the prior year's quarter.
- 3The company maintained a strong liquidity position with $1.3 billion in cash, cash equivalents, and short-term investments as of July 31, 2017.
- 4Operating expenses increased by 10% in Q3 FY2017, primarily due to increased headcount from acquisitions and higher product/consulting costs.
- 5Synopsys continued to execute its stock repurchase program, with $500 million remaining available as of July 31, 2017.
- 6A significant increase in upfront products revenue was observed, up 50% in Q3 FY2017, driven by hardware and IP product sales.
- 7The company is actively managing legal proceedings, notably a patent litigation with Mentor Graphics, for which it has accrued $39.0 million as a loss contingency.